EUVIMEDEUVIMED entdecken
Crossref

Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab

Claudia Campani iD, Jessica Bamba-Funck, Bertille Campion, Sabrina Sidali, Lorraine Blaise, Nathalie Ganne-Carrié, Alix Demory, Olivier Sutter, Edouard Larrey, Manon Evain, Haroun Ghannouchi, Mathilde Wagner und 4 weitere

Liver International · 2023-03 · 43 (3) · 708-717

DOI: 10.1111/liv.15487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 14.12.2022. Verfasst von Claudia Campani und 15 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris Cité, Team « Functional Genomics of Solid Tumors », Paris, Franc…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The combination of atezolizumab and bevacizumab (AtezoBev) is the current first‐line treatment for patients with hepatocellular carcinoma (HCC). Our aim was to evaluate the prognostic role of alpha‐foetoprotein (AFP) early response and its combination with albumin–bilirubin (ALBI) in these patients.

Methods

Patients with HCC under AtezoBev with AFP > 20 ng/ml were included in three centres. The optimal threshold of AFP variation after 3 weeks of treatment was identified for overall survival (OS) and radiological response (RR) using RECIST 1.1 and mRECIST and its ability to predict progression‐free survival (PFS) and OS was tested using univariate and multivariate analysis in derivation and validation cohorts.

Results

Seventy‐five patients with AFP values >20 ng/ml were included. Fifty‐eight patients were male with a median age of 63.5 years; 73% had cirrhosis and HCC stage was classified as BCLC B (18.7%) or C (81.3%). In the derivation cohort ( n = 38), a decline in AFP ≥ 20% at 3 weeks (AFP early response) was associated with RR using mRECIST criteria (OR: 13.09 95% CI: 1.44–19.34 p = .02), PFS (HR: 0.42; 95% CI: 0.19–0.93, p = .03) and OS (HR: 0.35; 95% CI: 0.15–0.83, p = .01). AFP early response was confirmed as predictor of RR ( p = .02 for mRECIST) and OS ( p = .03) in the validation cohort ( n = 37). In the whole cohort, the combination of ALBI and AFP early response was significantly associated with OS ( p = .046) and PFS ( p = .012) with a poor prognosis in patients belonging to the ALBI2‐AFP non‐responders class.

Conclusion

AFP early response at 3 weeks predicts oncological outcomes in HCC patients treated with AtezoBev and combination with ALBI grade refines prognostic discrimination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansMaleMiddle AgedFemalealpha-FetoproteinsBevacizumabBilirubinAlbuminsRetrospective StudiesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

advanced hepatocellular carcinomaalpha-foetoproteinatezolizumab-bevacizumabbiomarkerearly responseimmunotherapy

Substanzen

alpha-FetoproteinsBevacizumabBilirubinAlbuminsatezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris Cité, Team « Functional Genomics of Solid Tumors », Paris, France.
  • Equipe labellisée Ligue Nationale Contre le Cancer, Labex OncoImmunology, Paris, France.
  • Department of Experimental and Clinical Medicine, Internal Medicine and Hepatology Unit, University of Firenze, Florence, Italy.
  • Department of Biochemistry, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Paris, France.
  • INSERM U1148 LVTS, UFR SMBH, Université Sorbonne Paris Nord, Paris, France.
  • Service d'Hépato-Gastroentérologie, AP-HP Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière, Paris, France.

ORCID-Profile: Claudia Campani, Fabio Marra, Manon Allaire, Jean-Charles Nault

Zitieren

APA

Campani, C., Bamba-Funck, J., Campion, B., Sidali, S., Blaise, L., Ganne-Carrié, N., Demory, A., Sutter, O., Larrey, E., Evain, M., Ghannouchi, H., Wagner, M., Marra, F., Sutton, A., Allaire, M., & Nault, J. C. (2023). Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab. Liver International, 43(3), 708-717. https://doi.org/10.1111/liv.15487

Vancouver

Campani C, Bamba-Funck J, Campion B, Sidali S, Blaise L, Ganne-Carrié N, et al. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab. Liver International. 2023;43(3):708-717. doi:10.1111/liv.15487

BibTeX
@article{Campani2023,
  author = {Campani, Claudia and Bamba-Funck, Jessica and Campion, Bertille and Sidali, Sabrina and Blaise, Lorraine and Ganne-Carrié, Nathalie and Demory, Alix and Sutter, Olivier and Larrey, Edouard and Evain, Manon and Ghannouchi, Haroun and Wagner, Mathilde and Marra, Fabio and Sutton, Angela and Allaire, Manon and Nault, Jean-Charles},
  title = {Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab},
  journal = {Liver International},
  year = {2023},
  volume = {43},
  number = {3},
  pages = {708--717},
  doi = {10.1111/liv.15487}
}
Kostenlos starten →